Compare Gilead Sciences, Inc. (GILD) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Star Bulk Carriers Corp — how do they compare? Gilead Sciences, Inc. trades at $132.93 (market cap $163.51B), while Star Bulk Carriers Corp trades at $26.55 (market cap $2.94B). The key difference: Gilead Sciences, Inc. is far larger — about 55.6× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays the higher dividend (3.91%). Which is the better fit depends on your goals.
| GILD | SBLK | |
|---|---|---|
Market Cap | $163.51B | $2.94B |
Sector | Health | Industrials |
52-Week High | $155.80 | $28.21 |
52-Week Low | $108.22 | $16.79 |
Enterprise Value | $178.05B | $3.64B |
Dividend Yield | 2.49% | 3.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Star Bulk Carriers (SBLK) trades at $26.50, showing modest daily weakness with a 0.23% decline. The stock maintains a bullish technical outlook with strong moving average support, while recent earnings beats in Q4 2025 and Q1 2026 demonstrate operational strength. The company's modernizing fleet and dividend policy supporting yields above 10% provide attractive shareholder returns amid favorable dry bulk shipping rates.
SBLK presents compelling value with improving fundamentals and analyst optimism, though investors face risks from shipping rate volatility and cyclical industry exposure. The 58% buy rating consensus and projected profit margin expansion to 13% support upside potential, balanced by the need to monitor Q2 2026 earnings delivery against high expectations of $0.96 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
